Lighthouse Investment Partners LLC Takes $1.13 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Lighthouse Investment Partners LLC acquired a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXFree Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 52,199 shares of the company’s stock, valued at approximately $1,128,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CWM LLC raised its position in shares of Syndax Pharmaceuticals by 415.3% in the 4th quarter. CWM LLC now owns 1,685 shares of the company’s stock valued at $36,000 after purchasing an additional 1,358 shares during the last quarter. MeadowBrook Investment Advisors LLC purchased a new position in Syndax Pharmaceuticals during the 4th quarter worth approximately $37,000. Quadrant Capital Group LLC raised its position in Syndax Pharmaceuticals by 158.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock worth $53,000 after buying an additional 1,496 shares during the last quarter. Annandale Capital LLC purchased a new position in Syndax Pharmaceuticals during the 3rd quarter worth approximately $67,000. Finally, Signaturefd LLC raised its position in Syndax Pharmaceuticals by 2,874.6% during the 4th quarter. Signaturefd LLC now owns 3,748 shares of the company’s stock worth $81,000 after buying an additional 3,622 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on SNDX shares. HC Wainwright reissued a “buy” rating and set a $41.00 price target on shares of Syndax Pharmaceuticals in a research report on Thursday, June 6th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $34.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, May 21st. Stifel Nicolaus lifted their target price on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Finally, Citigroup cut their target price on shares of Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $34.42.

Get Our Latest Report on SNDX

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock opened at $19.72 on Tuesday. The company’s 50-day moving average price is $21.12 and its 200-day moving average price is $21.22. Syndax Pharmaceuticals, Inc. has a twelve month low of $11.22 and a twelve month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.11. During the same quarter last year, the firm posted ($0.59) earnings per share. Equities research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.57 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Recommended Stories

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXFree Report).

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.